ABBV 141
Alternative Names: ABBV-141Latest Information Update: 17 Mar 2025
At a glance
- Originator AbbVie
- Class Antifibrotics; Monoclonal antibodies
- Mechanism of Action Lysophosphatidic acid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis
Most Recent Events
- 17 Mar 2025 Phase-I clinical trials in Idiopathic pulmonary fibrosis in USA (IV) (AbbVie pipeline, March 2025)
- 17 Mar 2025 Phase-I clinical trials in Idiopathic pulmonary fibrosis in USA (SC) (AbbVie pipeline, March 2025)
- 30 Dec 2024 AbbVie completes a phase I trial for Healthy volunteers in USA (SC, IV) (NCT06148181)